Yonkenafil hydrochloride

Drug Profile

Yonkenafil hydrochloride

Alternative Names: Ecocarbamate hydrochloride; Gluconocin hydrochloride; Yonkenafil

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tasly Pharmaceutical Group; Yangtze River Pharmaceutical Group
  • Class Erectile dysfunction therapies; Piperazines; Pyrimidinones; Pyrroles; Small molecules; Sulfones
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Erectile dysfunction

Most Recent Events

  • 01 Jul 2017 Phase-I clinical trials in Erectile dysfunction (In volunteers) in China (PO) (ChiCTR-OIC17011807)
  • 01 Jul 2017 Yangtze River Pharmaceutical Group and Chinese PLA General Hospital plans a phase I trial for Erectile dysfunction (In volunteers) in China (ChiCTR-IIR17011814)
  • 26 Jun 2017 Chinese PLA General Hospital and Yangtze River Pharmaceutical Group initiates enrolment in a phase I trial in Erectile dysfunction (In volunteers) in China (ChiCTR-IIC17011805)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top